COVID-19 crisis: COVAX urgently needs 20 million vaccines to cover supply disruption, says WHO
COVAX urgently needs 20 million doses during the second quarter of 2021 to cover interruptions in supply triggered by increased demands for vaccines in India where COVAX's main supplier of the AstraZeneca product is based, according to WHO
Sri Lanka looking at sources other than India to buy AstraZeneca COVID-19 vaccine
Gen Shavendra Silva, chief of COVID prevention operations, said supply is being delayed from the Serum Institute of India in the wake of the current COVID crisis in the country
US won't release AstraZeneca's vaccine until sure about safety: Official
The US FDA will not release AstraZeneca's coronavirus vaccine for export to other countries until it is sure the doses have been manufactured to US quality standards and will be safe and effectiveIndia expects biggest' share of AstraZeneca vaccines from US
White House says 10 million doses could be cleared for export in coming weeks
Joe Biden admin under fire for not releasing surplus COVID-19 vaccines to India
Indian-American Congressman Raja Krishnamoorthi urged the Biden administration to release doses of the AstraZeneca vaccine to countries currently experiencing the deadly surge in COVID-19 cases.
Serum Institute of India defends Covid-19 vaccine pricing
Serum Institute of India (SII), which manufactures AstraZeneca's vaccine Covishield at its Pune facility, earlier this week announced a price of 600 per dose and at 400 for state governments and any new contract by the central governmentEMA calls for warning of very rare side-effects' on J&J; vaccine
Similar blood clot' cases were reported with AstraZeneca vaccine
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Launch Of Benralizumab 30Mg/Ml Solution For Injection (Fasenra(tm))
We refer to our earlier communication dated December 20, 2020 intimating the receipt of Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra(tm)) With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited has launched Fasenra(tm) in India on April 20, 2021. Benralizumab (Fasenra(tm)) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients. AstraZeneca Pharma India Ltd - 506820 - Shareholding for the Period Ended March 31, 2021
AstraZeneca Pharma India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here